These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27045058)

  • 1. Substances doubtful for bulk drug substances list could be INDs.
    Thompson CA
    Am J Health Syst Pharm; 2016 Apr; 73(8):512-4. PubMed ID: 27045058
    [No Abstract]   [Full Text] [Related]  

  • 2. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
    Simon LS; Green A
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Food and Drug Administration. "Evaluation Criteria" for Difficult to Compound Drugs.
    Allen LV
    Int J Pharm Compd; 2015; 19(6):487-8. PubMed ID: 26891563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
    Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
    [No Abstract]   [Full Text] [Related]  

  • 9. New FDA breakthrough-drug category--implications for patients.
    Ricart AD
    N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580
    [No Abstract]   [Full Text] [Related]  

  • 10. New FDA breakthrough-drug category--implications for patients.
    Velleca M
    N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579
    [No Abstract]   [Full Text] [Related]  

  • 11. New FDA breakthrough-drug category--implications for patients.
    Murray BE
    N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578
    [No Abstract]   [Full Text] [Related]  

  • 12. New FDA breakthrough-drug category--implications for patients.
    McClellan M; Sigal E
    N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577
    [No Abstract]   [Full Text] [Related]  

  • 13. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576
    [No Abstract]   [Full Text] [Related]  

  • 14. Notification vs approval.
    Novack GD
    Ocul Surf; 2007 Jul; 5(3):255-8. PubMed ID: 17660899
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
    Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues in the interpretation of 180-day exclusivity.
    Lietzan E; Korn DE
    Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
    [No Abstract]   [Full Text] [Related]  

  • 19. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.